ERBB2 and non-small cell lung carcinoma: Regarding NSCLC, no official guidelines have been developed for the assessment of HER2 positivity, and as a result, the evaluation of gene amplification and/or protein overexpression in clinical trials has been, until recently, performed via extrapolation from breast and gastric cancer.